Sep 17, 2021 9:11 am EDT Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares
Sep 14, 2021 10:23 pm EDT Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock
Aug 2, 2021 4:01 pm EDT Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
Aug 2, 2021 7:30 am EDT Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
Jul 26, 2021 4:01 pm EDT Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
Jun 23, 2021 7:30 am EDT Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
Jun 7, 2021 7:00 am EDT Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance
